Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propafenone
Drug ID BADD_D01856
Description An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Indications and Usage Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
Marketing Status approved
ATC Code C01BC03
DrugBank ID DB01182
KEGG ID D08435
MeSH ID D011405
PubChem ID 4932
TTD Drug ID D0J2KV
NDC Product Code 51407-478; 24979-086; 69680-130; 69680-131; 71205-942; 12598-6285; 71205-941; 24979-087; 24979-085; 51407-477; 71205-940; 69680-132; 51407-479
UNII 68IQX3T69U
Synonyms Propafenone | Propafenone Hydrochloride, (R)-Isomer | Rytmo-Puren | Rytmogenat | SA-79 | SA 79 | SA79 | Propafenone, (+-)-Isomer | Propafenone, (R)-Isomer | Propafenone, (S)-Isomer | Propamerck | Apo-Propafenone | Baxarytmon | Cuxafenon | Fenoprain | Jutanorm | Nistaken | Prolecofen | Propafenon AL | Propafenon Hexal | Propafenone Hydrochloride | Hydrochloride, Propafenone | Propafenone Hydrochloride, (S)-Isomer | Rythmol | Propafenon Minden | Norfenon | Pintoform | Rytmonorm | Arythmol
Chemical Information
Molecular Formula C21H27NO3
CAS Registry Number 54063-53-5
SMILES CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Food interaction08.06.03.0020.000627%Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Gamma-glutamyltransferase increased13.03.04.024--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.0030.000418%
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.0010.001421%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.000418%Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.0020.002926%Not Available
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Gingival pain07.09.13.010--
Glossitis07.14.01.001--Not Available
Glossodynia07.14.02.001--Not Available
Glycosuria20.02.01.005--
Gout14.09.01.001; 15.01.06.001--Not Available
Haematoma24.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.0060.000836%
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemolysis01.06.04.0020.000418%
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Headache17.14.01.001--
Heart rate irregular13.14.04.003--Not Available
Heart sounds abnormal13.14.01.002--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000418%Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis cholestatic09.01.01.0020.000836%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene